Protocol Ledger

NCT04871282 · Phase II/III · ACTIVE NOT RECRUITING

A Study of AL102 in Patients With Progressing Desmoid Tumors

Interventional Phase II/III clinical trial protocol NCT04871282 sponsored by Immunome in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-01 Enrollment: 198 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04871282
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)198 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04871282
Protocol FieldVerified Registry Value
NCT IdentifierNCT04871282
Consolidated Lead SponsorImmunome
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment198 participants (ACTUAL)
Registered Start Date2021-09-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI